The producer of an innovative system for breast cancer home preventive care published today its Issue Prospectus, drawn up on account of the initial Public Offering, approved by the Financial Supervision Authority on 4 July 2017. The subscriptions for individual investors are going to take place from 10 July to 17 July. The resources obtained from the Public Offering will be spent on the global expansion of the System of breast cancer home preventive care and on the development of the business in the area of telemedicine.
6 July 2017 BRASTER S.A. published its Issue Prospectus, approved by the Financial Supervision Authority, on 4 July 2017, on account of the Public Offering of stocks, without pre-emptive rights, covering at least 3,000,000 series I ordinary bearer stocks of the nominal value of PLN 0.10. Under the decision of the General Meeting, the new stocks will be first offered to the current Stockholders at the General Meeting on 20 April 2017 pro rata to their previous shares in the Company’s share capital. The maximum price of the stocks will be publicly announced after the Financial Supervision Authority approves the proper annex to the Issue Prospectus.
The subscriptions for stocks will start on Monday, 10 July. IPOPEMA Securities S.A. is going to be the stock Offeror. Individual investors will subscribe directly with the Offeror and with members of the retail consortium. The list of the places where one may submit a subscription order, as well as remaining documents regarding the Company and the Offer, will be available at the website of the Company: ri.braster.eu and of the Offeror: www.ipopemasecurities.pl.
"The funds from the issue of stocks will be mainly spent on the international expansion of our Company. We are planning to start sales in the first foreign markets, including Great Britain, as early as this year, and to initiate pilot projects in further countries. At the same time, we are awaiting the FDA approval for our application for marketing our Braster device on the US market." - says Marcin Halicki, President of the Management Board of BRASTER S.A. – "We are expecting that the recently presented updated strategy – clearly illustrating the attractiveness of the dynamically developing telemedicine market, and the huge commercial potential of our solutions on foreign markets – will encourage investors to take part in the upcoming Public Offering." – he adds.
Use of the revenue from the issue
BRASTER S.A. is planning to obtain PLN 54-63 million* from the issue of series I stocks within the Offering. The obtained funds will be earmarked for the following objectives, presented in accordance with their priority:
Expansion into foreign markets and day-to-day costs of Company management (PLN 45.6-47.1 million*)
After the publication of the current strategy for the years 2015-2021 in March, the Company is planning a debut in about a dozen foreign markets in the years 2017-2018. At the end of June/beginning of July, the Company informed of signing agreements related to the start of pilot projects in Ireland, Japan and Dubai. In the upcoming weeks, the Company is looking forward to signing further agreements in Portugal and the Netherlands. Apart from the pilot project countries, BRASTER would like to debut in Great Britain until the end of this year. If the consent of the FDA is obtained, the Company would like to enter the US market this year. It is also planning to start technical pilot projects in Canada, Brazil, China and India. BRASTER will enter more markets in 2018 (Germany, Korea). For the purpose of executing the expansion plan, it is necessary to incur expenditure, in particular on increasing the working capital, preparing and conducting the marketing campaigns, increasing the sales capacity, developing the IT infrastructure, adapting the Braster System to the requirements of the respective markets, as well as conducting the certification procedures and maintaining the operating capacities of the Company.
Until 2021, BRASTER is planning to have entered markets which guarantee access to over 21 million people from the specific target group. Until that time, foreign sales will have constituted over 90% of total sales.
Development of a global telemedicine platform (PLN 4.8-12.8 million*)
One of the strategic objectives of the Company is also to construct a global integrated telemedicine platform, apart from the Braster System, as well as telemedicine solutions and devices of other producers, characterized by global sales potential. The vision will be executed, among others, by potential acquisitions. The Company is interested particularly in producers of telemedicine devices, providers of e-health services and products and the companies that provide telemedicine services.
Purchase of a real property in Szeligi (PLN 3.5 million*)
In December 2016 BRASTER purchased a real property including a plot in Szeligi near Warsaw and the building situated on it, for the registered office of the Company and for conducting the process of manufacturing liquid crystal matrices. The real estate was purchased for the sale price of PLN 5.3 million. The payment was split into two instalments of: PLN 1.3 million and PLN 4 million. The Company paid the first instalment and some of the second one from a bank loan. The remaining amount of PLN 3.5 million is to be paid from the resources from the issue of new stocks.
6 July 2017 – Publication of the Prospectus
7 July 2017 – Publication of the Maximum Price
from 10 July to 17 July 2017 – Period of subscription submission by individual investors
from 10 July to 18 July 2017 – Book-building
18 July 2017 – Determination of the final number and price of the offered stocks
from 19 July to 21 July 2017 – Period of subscription submission by institutional investors
21 July 2017 – Stock award and transaction settlement
29 August 2017 – Planned date of listing the series I stocks in the Warsaw Stock Exchange
*the final values may change after the maximum price for the public offering is approved